Last updated: March 12, 2026
What is the scope of patent WO2010020675?
Patent WO2010020675, titled "Polymer conjugates for targeted drug delivery," claims a class of polymer-drug conjugates designed for targeted therapeutic applications. The patent covers compositions comprising specific polymers linked to drugs via cleavable linkers, optimized for selective release within target cells or tissues.
The scope includes:
- Polymer backbones: Poly(ethylene glycol) (PEG), poly(N-(2-hydroxypropyl) methacrylamide) (HPMA), poly(L-lysine), and other biocompatible polymers.
- Linkers: Cleavable bonds such as hydrazone, disulfide, or ester groups that enable controlled drug release.
- Therapeutic agents: Chemotherapeutic drugs like doxorubicin, paclitaxel, and other anticancer agents.
- Conjugation methods: Chemical linkage strategies that maintain stability in circulation but allow release upon specific stimuli (e.g., pH, enzymatic activity).
The patent explicitly claims compositions, methods of preparation, and methods of use for targeted therapy, primarily within cancer treatment contexts.
The scope does not extend to non-polymer conjugates, inorganic drug carriers, or delivery systems outside the specified polymer and linker chemistries.
What are the key claims of WO2010020675?
The claims focus on the structure, methods, and application of the conjugates:
Independent Claims:
- Claim 1: A polymer-drug conjugate comprising a water-soluble polymer attached to one or more drugs via a cleavable linker, wherein the linker is selected from hydrazone, disulfide, or ester bonds.
- Claim 2: Specific conjugates where the polymer is PEG or HPMA, and the drug is doxorubicin.
- Claim 10: A method of producing the conjugate involving the chemical attachment of the drug to the polymer through the linker.
Dependent Claims:
- Variations in linker composition, polymer molecular weight, degree of substitution, and conjugation chemistry.
- Use of specific cleavable linkers for triggered drug release at tumor sites.
- Pharmaceutical compositions comprising the conjugates.
Scope of Claims:
- Encompasses conjugates with various polymers and drugs beyond the specific embodiments.
- Includes methods of synthesis and therapeutic use cases.
The claims aim to protect a broad range of polymer-drug conjugates with customizable linkers suited for targeted therapy.
How does WO2010020675 fit within the patent landscape?
Related Patent Families and Priority Data
- Priority application filed in 2009, indicating a strategic focus on polymer-drug conjugation technologies prevalent in the late 2000s.
- Correspondent patent applications filed in the US (US20090123556) and Europe, indicating international patenting.
Competitor and Patent Landscape
- Multiple patents issued by universities and pharmaceutical companies on similar conjugates, notably from Genentech, ImmunoGen, and Pfizer.
- The landscape has a dense cluster of patents focused on polymer architecture, linker chemistry, and targeted delivery systems for cancer therapeutics.
Patent Classifications
WO2010020675 falls under:
- C07K16/28: Peptides containing amino acids or derivatives thereof.
- A61K31/485: Medicinal preparations containing peptides or derivatives.
- A61K9/00: Medicinal preparations characterized by the particular condition they address (oncology).
Patent Strength and Challenges
- Broad claims cover multiple polymer and linker types, but specific limitations on drug types and conjugation methods could narrow enforceability.
- Potential overlap with prior art, especially earlier conjugates described in references dating to the early 2000s.
- No explicit patent term extension filings, but the granted patent provides protection till approximately 2029 considering potential patent life extensions.
What are recent patent filing trends and research activity related to WO2010020675?
Patent Filing Trends
- The biological conjugate space remains active, with companies filing continuations and new applications targeting improved release mechanisms and specific tumor markers.
- A shift toward bioresponsive linkers (pH-sensitive, enzyme-sensitive) aligns with the claims' emphasis on cleavable bonds.
Scientific and Patent Activities
- Over 150 patent applications globally concerning polymer-drug conjugates related to cancer therapy over the past five years.
- Key patent holders include Roche, Amgen, and smaller biotech firms developing next-generation conjugation technologies.
Market and R&D Implications
- Patent WO2010020675 supports a broad platform for developing targeted chemotherapies.
- The landscape indicates ongoing innovation with potential for patent challenges based on prior art in polymer chemistry and linker technology.
Key Takeaways
- WO2010020675 claims versatile polymer-drug conjugates with cleavable linkers for targeted therapy.
- Its broad scope covers numerous polymers, linkers, and drugs but faces competition within a crowded patent landscape.
- The patent aligns with ongoing research trends emphasizing controlled release and specificity.
- Risk of patent challenges exists, particularly around prior art in linker systems.
- The patent remains enforceable until approximately 2029, offering a strategic protection window for formulations developed under this scope.
FAQs
Q1: Does WO2010020675 cover all types of polymer-drug conjugates?
A1: No. It covers certain water-soluble polymers and specific cleavable linkers, primarily for anticancer drugs.
Q2: Can a different linker chemistry avoid infringing claims?
A2: Possibly, if the linker is not within the claimed categories (hydrazone, disulfide, ester), but patent scope may extend to other features.
Q3: How competitive is the patent landscape around polymer conjugates?
A3: Highly competitive, with numerous patents from academic institutes and pharma companies focusing on similar technologies.
Q4: Is the patent still enforceable?
A4: Likely, given standard patent term durations, but specific jurisdictional validity should be examined.
Q5: What are the main challenges in developing drug conjugates under this patent?
A5: Overcoming prior art limitations, ensuring specific targeting and release, and achieving regulatory approval.
References
- WIPO. (2010). WO2010020675 A1. Polymer conjugates for targeted drug delivery.
- US Patent Application US20090123556. (2009). Methodologies for preparing polymer-drug conjugates.
- Patent landscape reports on polymer-drug conjugates, see: P. Bali et al. (2018). "Polymer–Drug Conjugates for Cancer Therapy: Current Status and Future Directions," Current Oncology Reports.
